RuiMing Pharma Successfully Completes Phase I Clinical Trial of RMP-A03 Ophthalmic Solution for Pterygium in the U.S.

Recently, Suzhou Raymon Pharmaceuticals Company, Ltd. (hereinafter referred to as "Raymon Pharma") announced that itsRMP-A03 Eye Drops, Independently Developed by Raymon Pharma for the Treatment of Pterygium, Successfully Complete Phase I Clinical Trial in the United States, and achieved excellent results.RMP-A03 eye drops are also the second self-innovated drug in Suzhou Raymon Pharmaceuticals Company, Ltd.'s R&D pipeline to enter clinical trials.

Pterygium is the abnormal proliferation and growth of conjunctival blood vessels and epithelial cells at the corneoscleral limbus, which then invades the cornea, making it a common ocular disease in the population. The prevalence of pterygium ranges from 0.074% in Saudi Arabia to 53% in Taiwan, China, with a global comprehensive prevalence of 12%. To date, there is no effective drug treatment for pterygium, and the widely used clinical treatment is surgical excision, but the postoperative recurrence rate is relatively high. Effectively controlling pterygium in its early stages and reducing postoperative recurrence are critical issues that need to be urgently addressed in clinical practice.

VEGF is one of the most common growth factors in ophthalmic diseases, and an important growth factor with pro-angiogenic activity. It promotes mitosis and anti-apoptosis in endothelial cells, increases vascular permeability, and facilitates cell migration, among other functions. Pterygium is a fibrovascular hyperplastic lesion, and its excessive cell proliferation and angiogenesis are closely related to the high expression of VEGF. RMP-A03 eye drops inhibit the formation of new blood vessels and fibroblasts in pterygium by suppressing pathways mediated by relevant targets, thereby eliminating pterygium lesions and preventing pterygium recurrence.

This Phase I clinical trial is an open-label study aimed at evaluating its safety in healthy adult subjects. Data from the Phase I clinical trial showed that in the multiple-dose escalation study, the eye drop demonstrated good safety and tolerability across all dose groups. No adverse events occurred during the study period, indicating that the eye drop exhibited excellent safety and tolerability in the subjects.

Dr. Zhang Fei

Founder of Raymon Pharma

Dr. Zhang Fei, founder of Raymon Pharma, stated:

RMP-A03 Eye Drops is the second self-innovated drug in Raymon Pharma's R&D pipeline to enter clinical trials. The successful completion of Phase I clinical trial in the United States fully demonstrates Raymon Pharma's capability in global clinical research. We will accelerate the subsequent clinical development process of the project and look forward to RMP-A03 Eye Drops playing a role in the prevention, treatment, and reduction of recurrence of pterygium worldwide.

About Raymon Pharma

Raymon Pharma is a company focused on the research and development of innovative ophthalmic drugs. Its founders and management team have many years of top-tier R&D and management experience in multinational pharmaceutical enterprises and have participated in the development of multiple ophthalmology clinical projects. Since its establishment, the company has adhered to independent innovation, committing itself to new drug research and clinical studies for ophthalmic diseases while exploring various types of eye conditions. In the future, Raymon Pharma will continue to uphold the concept of "Technology Benefits Health," targeting areas of unmet clinical needs, further expanding new pipelines, and promoting the research of innovative ophthalmic drugs.

Copyright © 2023 PHARMCUBE. All Rights Reserved.

Welcome to forward, share, and reasonably cite. When citing, please clearly indicate the source of the article; if you need to reprint, please leave a message or send a message to the WeChat Official Account backend, and include the name and ID of the official account.

Disclaimer: The information in this WeChat article is for general reference only and should not be directly used as decision-making content. Medicine Cube assumes no responsibility for any loss incurred by any party due to the use of the content herein.

Medcube Reader Survey Questionnaire

Thank You for Your Support. We Look Forward to Your Feedback.

Scan QR Code to Provide Valuable Suggestions